| Source: |
Escherichia coli. |
| Molecular Weight: |
Approximately 19.7 kDa, a single non-glycosylated polypeptide chain containing 180 amino acids. |
| AA Sequence: |
SPLPITPVNA TCAIRHPCHN NLMNQIRSQL AQLNGSANAL FILYYTAQGE PFPNNLDKLC GPNVTDFPPF HANGTEKAKL VELYRIVVYL GTSLGNITRD QKILNPSALS LHSKLNATAD ILRGLLSNVL CRLCSKYHVG HVDVTYGPDT SGKDVFQKKK LGCQLLGKYK QIIAVLAQAF |
| Purity: |
> 98% by SDS-PAGE and HPLC analyses. |
| Biological Activity: |
Fully biologically active when compared to standard. The ED50 as determined by the dose-dependent proliferation of human TF-1 cells is less than 0.1 ng/mL, corresponding to a specific activity of > 1.0 × 107 IU/mg. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH7.4. |
| Endotoxin: |
Less than 1 EU/μg of rHuLIF as determined by LAL method. |
| Reconstitution: |
Centrifuge the vial briefly before opening to ensure that the contents settle at the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-0.2 mg/mL. Divide the resulting stock solution into working aliquots and store them at or below -20°C. For further dilutions, use appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Synonyms: |
Differentiation-stimulating Factor, D Factor, Melanoma-derived LPL Inhibitor, MLPLI |
| Background: |
Belonging to the Interleukin 6 family, Leukemia Inhibitory Factor (LIF) is predominantly found in the outer layer of the developing embryo, known as the trophectoderm, and its receptor, LIFR, is present in the inner cell mass. LIF is capable of prompting leukemic cells to undergo final differentiation. It plays multiple roles, including promoting hematopoietic differentiation in both normal and myeloid leukemia cells, driving neuronal cell differentiation, and triggering acute-phase protein production in liver cells. In the context of mouse embryonic stem cell culture, LIF removal encourages differentiation while maintaining the cells' ability to proliferate or remain pluripotent. Additionally, LIF is part of a phase II clinical trial aimed at aiding embryo implantation in women who have experienced unsuccessful pregnancies despite using assisted reproductive technologies (ART). The mature human LIF protein shares a high degree of sequence identity with its counterparts in other species, including mice, rats, dogs, cows, and pigs. |
